Viral Hepatitis

Latest Articles

Direct-Acting Antiviral Therapy and a Reduction in Extrahepatic Manifestations of HCV

By

Virginia A. Schad, PharmD, RPh

Researchers reviewed the effects of direct-acting antiviral therapies on the extrahepatic manifestations of HCV.

Multidose ARC-520 May Reduce Surface Antigens, Viral RNA in Chronic HBV

By

Rita Aghjayan

Researchers aimed to characterize serological, virological, and histological profiles during and after multidose ARC-520 treatment in patients with chronic HBV.

HCC: Does Exposure to DAAs Affect Recurrence Risk

By

Rita Aghjayan

Investigators conducted an international, multicenter meta-analysis to assess HCC recurrence risk in patients treated with DAAs.

HCV Screening and Treatment Program in Low-to-Middle Income Country Deemed Successful

By

Jessica Nye, PhD

Researchers launched a simplified model of HCV care through decentralized health services within rural Cambodia.

High Prevalence of HCV Infection in MSM Regardless of HIV Status

By

Estie Mermelstein, MSN, FNP-BC

The researchers’ objective was to determine the prevalence of HCV antibodies among MSM with and without HIV, as well as factors associated with HCV infection among MSM.

FDA: 'Real Water' Alkaline Water May Be Linked to Hepatitis Outbreak

All five patients were hospitalized but have since recovered.

SVR Reduces Extrahepatic Complication Risk From HCV, Especially in Women

By

Virginia A. Schad, PharmD, RPh

A team of investigators examined differences in outcomes according to sex in risk for acute coronary syndrome, end-stage renal disease, and ischemic stroke by treatment and response in a large US-based multisite cohort of patients with hepatitis C virus infection.

Use of Direct Acting Antivirals With Potent Inducers Examined in Case Series

By

Cassandra Pardini, PharmD

While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.

Short-Term Glecaprevir/Pibrentasvir Safe, Efficacious for Treatment-Naive HCV

By

Bradley van Paridon

Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.

HBV Screening Beneficial in Immunocompromised Pediatric Patients With Rheumatologic Conditions and IBD

By

Amit Akirov, MD

Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.

ASCO Issues Provisional Opinion Update on Hepatitis B Screening

By

Leah Lawrence

ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.

CDC Releases Guidelines for Occupational Exposure to HCV

By

Zahra Masoud

New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.

CDC Guidance Issued for Testing, Management of Healthcare Personnel Exposed to HCV

Recommendations are presented for testing and clinical management of health care personnel exposed to the hepatitis C virus in a US Centers for Disease Control and Prevention guidance report.

Routine Hepatitis C Testing at Federally Qualified Health Centers Would Be Cost-Effective

Routine hepatitis C virus testing at federally qualified health centers would be cost-effective and could improve outcomes for people with HCV infections.

Efficacy of Bundled HIV, HCV Testing Examined in Substance Abuse Disorders

By

Bradley van Paridon

By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.

Small Case Series Describes Clinical Course of Patients With COVID-19 and Chronic HBV

By

Brandon May

Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.

Tenofovir Disoproxil Fumarate Associated With Higher Rates of Elastographic Reversion in Patients With Hepatitis B

By

Jessica Nye, PhD

TDF therapy resulted in greater rates of elastographic reversion of cirrhosis in patients with chronic hepatitis B at year 5 compared with entecavir.

Combined Hepatitis A/Typhus Vaccine, Safe and Tolerable For Children

By

Bradley van Paridon

A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.

Besifovir Dipivoxil Maleate Effective, Safe for Long-Term Treatment of Hepatitis B

By

Emily Pond

Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).

Statin Use and Acute Liver Injury Among Veterans With and Without HCV, HIV

By

Bradley van Paridon

Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.